Xie Jiafeng, Lei Ruyi, Pei Hui, Gu Yulei, Zhang Luanluan, Liu Jingrong, Huang Yahui, Zhang Yepeng, Zi Yanan, Zhu Changju, Zhu Zhiqiang
Department of emergency ICU, the first affiliated hospital of Zhengzhou University, Henan, 450052, China.
Henan Medical Key Laboratory of Emergency and Trauma Research, Henan, 450052, China.
Sci Rep. 2025 Jan 2;15(1):150. doi: 10.1038/s41598-024-84600-z.
The study was to explore the efficacy and safety of sivelestat (SV) in the treatment of severe acute pancreatitis (SAP) with systemic inflammatory response syndrome (SIRS). A total of 102 SAP patients diagnosed and treated in the Emergency Intensive Care Unit of the First Affiliated Hospital of Zhengzhou University from January 2021 to August 2024 were selected. The changes of disease outcome, hospital stays and mortality were compared between the two groups. A total of 102 patients were recruited to control group (n = 56) or SV group (n = 46) according to whether SV was applied or not. There was no significant difference in baseline data at admission between the two groups. After 1 week of treatment, all the indexes in both groups improved. The duration of ventilator use (p = 0.0400) and ICU stays (p = 0.0495) in SV group was shorter than that in control group, but there was no significant difference in mortality between the two groups. Although SV did not reduce the mortality of patients with SAP, it reduced the length of ventilator use and ICU stay.
本研究旨在探讨西维来司他（SV）治疗伴有全身炎症反应综合征（SIRS）的重症急性胰腺炎（SAP）的疗效和安全性。选取2021年1月至2024年8月在郑州大学第一附属医院急诊重症监护病房诊断并治疗的102例SAP患者。比较两组患者的疾病转归、住院时间和死亡率。根据是否应用SV，将102例患者分为对照组（n = 56）和SV组（n = 46）。两组患者入院时的基线数据无显著差异。治疗1周后，两组各项指标均有所改善。SV组的呼吸机使用时间（p = 0.0400）和ICU住院时间（p = 0.0495）均短于对照组，但两组患者的死亡率无显著差异。虽然SV未降低SAP患者的死亡率，但缩短了呼吸机使用时间和ICU住院时间。
